In severely ill hemodialysis patients with Omicron COVID-19, thymalfasin use was linked to a higher probability of discharge (adjusted odds ratio 1.472).
In plain wordsIn severely ill dialysis patients with COVID-19, thymalfasin use was linked to a higher chance of leaving hospital alive.
- Peptide
- Thymosin alpha-1
- Outcome
- IncreaseProbability of discharge in severely ill patients
- Study
n: not reported in source
- Outcome group
- Mortality · Infection
- Studied dose
- Dose not stated
Measurements
- adjusted odds ratio, discharge
- 1.472 aOR
- thymalfasin
Source sentences
The drugs thymalfasin and Tanreqing significantly increased the probability of discharge for patients (aOR: 1.472; aOR: 3.104), with the latter having a higher correlation, but with a relatively longer effective course.
2 context sentences(design, population, supporting numbers)
Clinical and biochemical indicators of 219 hemodialysis patients infected with the Omicron variant were statistically analyzed.
The severely ill patients were then grouped based on discharge or death, and the treatment drugs were included as influencing factors for multiple regression analysis to determine the risk factors and protective factors for death of severely ill patients, and drug efficacy analysis was conducted.